Hungry for progress - appetite, genes and drugs (HD) | A film ...
Why do we sensation hunger, what drives some people to eat to dissipation and is there anything scientists can do about it? In this film, we meet several ...
New drug target for Parkinson's
Researchers have discovered that blocking a protein called LRRK2 in mice can intercept the symptoms of Parkinson's infirmity. The hunt is now on ...
ASHG 2010 Mtg.: "Epigenetics of Drug Addiction" (Dr. Eric ...
TO Examination THE FULL WEBCAST OF THIS SESSION, GO TO: www.ashg.org ASHG 2010 Annual Conference Concurrent Invited Session II: "Methylating the Sit with ...
Biologics, Biotechnology Therapies Are Focus of USP Symposium on Drug Quality ...
Product Class Quality, Bioassays, Regulatory Issues Related to Monoclonal Antibodies, Cell Therapies, and Other Biologics to Be Addressed
Rockville, MD (PRWEB) September 06, 2011
Increasingly used to treat certain advanced-stage cancers, chronic inflammatory diseases, and complex disorders such as cystic fibrosis, biologic and biotechnology products are providing answers to some of the unmet needs for a growing list of diseases. Collectively referred to as "biologics," these therapies are also being used in some cases where traditional medical treatments are no longer viable options for patients. This year, the U.S. Pharmacopeial Convention (USP) will dedicate its annual scientific symposium to the important area of quality standards for biologic and biotechnology-based drugs.
Taking place October 3-6, 2011, in Seattle, Wash., USP's Science & Standards Symposium on Biologics and Biotechnology will open with a keynote event, "How the World Regulates Biologics," featuring Steven Kozlowski, M.D., director of the Office of Biotechnology Products in the Office of Pharmaceutical Science in the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration (FDA), and Gillian Woollett, Ph.D., chief scientist at the Washington, D.C., law firm Engel & Novitt, LLP. The session will be a point-counterpoint, focusing on biosimilars-drugs similar to and also potentially interchangeable with innovator biologics previously approved by FDA. USP is a private, nonprofit, scientific organization that develops standards for the quality of medicines manufactured or sold in the U.S., and compliance to USP's standards is enforceable by FDA. (For preview video highlights, visit: http://bit.ly/qUIRVq ).
Electric field propels worms to test new drugs | Science Blog
A Nobel-successful operation for testing new drugs to handling of diseases such as Huntington's, Parkinson's, and brawny dystrophy is getting an electrical invoice.
Researchers at McMaster University have developed a way to thrust and steer microscopic-sized worms (C. elegans nematodes) along a limited watercourse using a gentle galvanizing meadow. The exploration opens up substantial possibilities for developing considerable-throughput micro-screening devices for numb origination and other applications.
"This is the first mores that worms have been stimulated to move in a micro-convey contraption in a very rigorous and directed way," said Bhagwati Gupta, allied professor of biology. "It will put up with researchers to observe in verified period how a proposed dose affects neurons and muscles that govern suggestion of a real instance."
The research is described in the January 21, 2010 outflow of Lab on a Chisel, a primary oecumenical album in the province of nanotechnology and bioengineering. The researchers present progress of the worms first and in upset basically a microchannel, guided by the rule of the tense sward (electrotaxis).
"The electrotaxis of the worms has the capacity to automate what is currently a backward, directions proceeding for pharmaceutical screening on worms," said Ravi Selvaganapathy, fellow professor of perfunctory engineering. "The system is utterly tractable and economical to proportion up to handling speedy screening of tens of thousands of chemicals in worms to associate opiate candidates in a set someone back-efficient amenities. Such recognition could accelerate clinical trials in people by allowing scientists to fuzzy only on appropriate drugs and would use reduced resources more efficiently."
Currently, researchers pore over worms severally under a microscope as they move in a stray proprieties or in a way feigned by coerce. The new situation retains a worm's organically grown action and causes no damage to the worm.
A surprising survey was that the retort of the worms was dependent on its age and neuronal expansion. This allows for stocky numbers of worms to be sorted and handled in an automated style.
...Science Research Drugs - News
Research into mutant flu 'must go on'
NewsPoint AfricaResearch into mutant flu 'must go on'One of the scientists at the focus of the controversy over the creation a highly dangerous form of bird flu which could induce a devastating human pandemic has denounced attempts by the US Authority to censor the research over fears that the findings Lab-grown super flu a gift, not threatMutant Flu Research Must Keep on for the Betterment of ScienceYoshihiro Kawaoka: Bird flu broadcasting research “must go on”all 35 news articles »
|
|
VGX-100 Identified as Potential New Therapy for Improving Corneal Graft Survival Since its inception, it has trained more than 600 postdoctoral fellows in many disciplines of eye research; trained more than 500 eye surgeons who now practice around the just ecstatic; and published more than 4600 scientific papers and books about constitution and more » |
DNDi and Abbott expand partnership to boost innovation for neglected tropical ...
Sky NewsThe Drugs for Neglected Diseases enterprise (DNDi) and Abbott have signed a four-year joint research and non-closed licensing agreement to undertake research on new treatments for several of the world's most neglected tropical diseases, Components R&D gaps key to succeeding in NTD control and elimination goals by 2020Johnson & Johnson Joins Mrs Average and Private Partners in the Largest Coordinated all 92 tidings articles »
|
Mind-altering drugs research call from Prof David Nutt
Telegraph.co.ukHowever, he said they were not being conscious because of the restrictions placed on researching illegal drugs. His comments followed the bimonthly of new research by his group in the Proceedings of the National Academy of Sciences, which suggests that Shrooms may announce the doors of perception, seriouslyYour Brain On Psilocybin Might Be Less DepressedActive Factor in 'Magic Mushrooms' May Be Therapeutic - -all 234 word articles »
|
|
India, Tunisia to launch joint research projects in biotechnology, medical science India and Tunisia will found joint research programmes in the field of biotechnology, medical sciences and other allied sectors of the science and technology with a aspect to find out and promote areas of joint research beneficial to the people in both |
